

SUPPLEMENT

Table S1. Logistic regression: outcome: 30-day neurologic function defined by Cerebral Performance Categories (CPC) 1 and 2.

| Favorable neurological outcome CPC 1 and 2 | Odds ratio (95% confidence intervals) | p-value |
|---|--|----------------|
| PCSK-9 ≥ 165mg/dL | 4.72 (1.76–12.66) | 0.002 |
| PCSK-9 ≥ 165mg/dL | 3.67 (1.32–10.16) | 0.013 |
| C-reactive protein > 0.5mg/dL at admission | 2.48 (0.81–7.65) | 0.114 |
| PCSK-9 ≥ 165mg/dL | 4.38 (1.61–11.87) | 0.004 |
| Sex | 0.45 (0.14–1.51) | 0.20 |
| PCSK-9 ≥ 165mg/dL | 4.46 (1.61–12.38) | 0.004 |
| Age (years) | 1.04 (1.00–1.08) | 0.041 |
| PCSK-9 ≥ 165mg/dL | 4.73 (1.48–15.18) | 0.009 |
| No-flow time (min) | 1.13 (0.90–1.42) | 0.293 |
| PCSK-9 ≥ 165mg/dL | 5.199 (1.84–14.71) | 0.002 |
| Initial shockable rhythm | 0.26 (0.08–0.89) | 0.032 |

PCSK-9, proprotein convertase subtilisin/kexin type 9.

Table S2. Baseline Characteristics: Categorical data are presented as counts and percentages, continuous data as medians and interquartile ranges (IQRs).

| Baseline Characteristics. | Total (<i>n</i> = 79) | PCSK9-levels (ng/mL) | | <i>p</i> |
|---|---------------------------|--------------------------|--------------------------|----------|
| | | <180 (<i>n</i> = 32) | ≥180 (<i>n</i> = 47) | |
| Gender, male <i>n</i> (%) | 61 (77) | 27 (84) | 34 (72) | .214 |
| Age, years (IQR) | 59 (46–69) | 56 (45–65) | 59 (51–70) | .169 |
| Concomitant diseases, <i>n</i> (%) | | | | |
| Hyperlipidemia | 20 (25) | 6 (19) | 14 (30) | .271 |
| DM II | 16 (20) | 7 (22) | 9 (19) | .769 |
| Coronary artery disease | 16 (20) | 7 (22) | 9 (19) | .769 |
| Hypertension | 31 (39) | 13 (41) | 18 (38) | .836 |
| Smoker | 26 (33) | 10 (31) | 16 (34) | .797 |
| COPD | 8 (10) | 3 (9) | 5 (11) | .560 |
| PAD | 6 (8) | 0 (0) | 6 (13) | .037 |
| Statine-use, <i>n</i> (%) | 14 (18) | 3 (9) | 11 (23) | .111 |
| CPC 1/2, <i>n</i> (%) | 36 (46) | 20 (63) | 16 (34) | .013 |
| Witnessed, <i>n</i> (%) | 64 (81) | 25 (78) | 39 (83) | .454 |
| BLS, <i>n</i> (%) | 55 (70) | 22 (69) | 33 (70) | .663 |
| Initial shockable rhythm, <i>n</i> (%) | 59 (75) | 25 (78) | 34 (72) | .564 |
| Time to sustained ROSC, min (IQR) | 25 (17–43) | 23 (14–43) | 28 (20–42) | .205 |
| No-flow time, min (IQR) | 0.0 (0.0–3.0) | 0.0 (0.0–2.1) | 0.0 (0.0–3.0) | .808 |
| Low-flow time, min (IQR) | 25.0 (16.0–40.5) | 22 (11–41) | 25 (20–41) | .262 |
| 30-day survival, <i>n</i> (%) | 53 (67) | 27 (84) | 26 (55) | .007 |
| Core body temperature (admission), °C (IQR) | 35.3 (34.8–35.8) | 35.5 (34.9–35.9) | 35.1 (34.7–35.6) | .223 |
| Blood gas values (admission) | | | | |
| pH (IQR) | 7.16 (7.04–7.25) | 7.16 (7.00–7.22) | 7.16 (7.05–7.25) | .996 |
| Lactate, mmol/L (IQR) | 7.6 (5.2–10.0) | 7.25 (4.8–10.1) | 7.7 (5.9–9.9) | .577 |
| Laboratory values (admission) | | | | |
| Hemoglobin, g/dL (IQR) | 13.9 (12.4–15.3) | 14.1 (12.5–15.3) | 13.8 (12.3–15.3) | .809 |
| Total Platelet count, G/L (IQR) | 205 (169–245) | 226 (175–252) | 200 (163–245) | .419 |
| Leukocytes, G/L (IQR) | 14.3 (10.5–18.9) | 14.6 (9.1–18.9) | 14.2 (10.8–19.1) | .822 |

| | | | | |
|---------------------------------|------------------|------------------|------------------|------------|
| Troponin-T, ng/L (IQR) | 64 (32–244) | 113 (37–367) | 53 (27–195) | .187 |
| Prothrombin-time, % (IQR) | 77 (65–91) | 72 (59–83) | 81 (66–91) | .162 |
| TG, mg/dL (IQR) | 125 (81–173) | 111 (82–159) | 136 (78–180) | .221 |
| Creatinin, mg/dl (IQR) | 1.1 (0.9–1.3) | 1.2 (0.9–1.3) | 1.1 (0.9–1.3) | .830 |
| Albumin, g/L (IQR) | 38 (34–40) | 39 (36–41) | 38 (33–40) | .102 |
| Cholinesterase, kU/L (IQR) | 6.70 (5.4–8.0) | 6.76 (4.96–7.96) | 6.71 (5.64–8.32) | .371 |
| Total cholesterol, mg/dL (IQR) | 163 (133–201) | 158 (138–182) | 168 (128–212) | .775 |
| ASAT (GOT), U/L (IQR) | 135 (78–226) | 136 (78–180) | 135 (80–269) | .708 |
| ALAT (GPT), U/L (IQR) | 112 (56–200) | 106 (64–166) | 129 (54–210) | .526 |
| Laboratory values | | | | |
| PCSK-9 (admission), ng/ml (IQR) | 193 (145–239) | 128 (118–153) | 226 (201–270) | .000 |
| PCSK-9 (12h), ng/ml (IQR) | 210 (151–267) | 161 (130–223) | 240 (203–303) | .000 |
| PCSK-9 (24h), ng/ml (IQR) | 187 (198–457) | 150 (114–220) | 202 (174–247) | .005 |
| NSE (admission), µg/L(IQR) | 575 (575–575) | <i>n.a</i> | 575 (575–575) | <i>n.a</i> |
| NSE (24h), µg/L (IQR) | 33.1 (21.4–54.4) | 30.2 (20.9–43.1) | 36.6 (21.8–57.6) | .374 |
| S-100 (admission), µg/L (IQR) | 3.78 (3.78–3.78) | <i>n.a</i> | 3.78 (3.78–3.78) | <i>n.a</i> |
| S-100 (24h), µg/L (IQR) | 0.15 (0.09–0.36) | 0.11 (0.08–0.16) | 0.19 (0.11–0.57) | .005 |
| CRP (admission), mg/dL (IQR) | 0.2 (0.1–0.6) | 0.2 (0.1–0.3) | 0.3 (0.1–0.9) | .041 |
| CRP (12h), mg/dl (IQR) | 0.99 (0.6–1.6) | 0.9 (0.5–1.1) | 1.3 (0.7–2.2) | .035 |
| CRP (24h), mg/dl (IQR) | 4.2 (2.8–6.1) | 3.8 (2.7–5.6) | 4.3 (2.8–8.0) | .384 |

CPC, cerebral performance category; DM II, diabetes mellitus II; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; BLS, basic life support; ROSC, return of spontaneous circulation; PCSK-9, proprotein convertase subtilisin/kexin type 9; TG, triglycerides; ASAT, aspartate aminotransferase; GOT, glutamate oxalacetate transaminase; ALAT, alanine aminotransferase; GPT, glutamate pyruvate transaminase; CRP, C-reactive protein; NSE, neuron-specific enolase.